FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594672174> ?p ?o ?g. }

• W2594672174 abstract "Background: Patient-reported outcomes (PROs) independently and directly describe patient (pt) treatment experiences, complement clinician reports, and are increasingly included in drug development. Eribulin (E) has activity in metastatic breast cancer (MBC) previously treated with > 2 regimens. Limited data are available on the activity of E in earlier lines. This phase II single arm study evaluated the activity, safety, and PROs of E in an earlier line setting for HER2- MBC. Methods: Eligible pts had HER2- MBC, 0-1 prior lines of chemotherapy, and enrolled into one of two parallel cohorts: HR+, TNBC. E was dosed 1.4 mg/m 2 weekly, 2 wk on/1 wk off; 1 cycle = 3 wks. The primary objective was overall response rate (ORR); additional objectives included progression-free survival (PFS) and safety. Correlative PRO endpoints included description and comparison of toxicity evaluation by PROs vs provider-report for degree of concordance or divergence for each class of toxicity, and description of QOL over time. Neuropathy was evaluated by the FACT-Neurotoxicity subscale, as well as exploration of predictive host polymorphisms. PRO instruments (PRO-CTCAE, FACT-B and FACT-NTX) were administered electronically at baseline, cycles 1-3, then every other cycle. Results: 83 pts enrolled: 45 HR+ and 38 TNBC. Median age was 56 (range: 34-87). 55.4% were first line, and 66% had received previous taxane in the adjuvant or metastatic setting. ORR for all pts was 25.3% (90% CI: 18%-34%); 35.6% in HR+ (90% CI: 24%-49%) and 13.2% in TNBC (90% CI: 5%-26%). mPFS estimate was 5.8 months (mo) for all pts, HR+ 6.2 mo (90% CI: 5.9-8.7) and TNBC 4.0 mo (90% CI: 3.5-4.8). Related toxicities occurring in > 20% of pts were: fatigue (61.4% overall, 32.5% G1, 27.7% G2, 1.2% G3), alopecia (51.8% overall, 16.9% G1, 32.5% G2), nausea (39.8% overall; 26.5% G1, 12.0% G2, 1.2% G3), peripheral sensory neuropathy (36.1% overall; 18.1% G1, 13.3% G2, 4.8% G3), decreased neutrophil count (32.5% overall; 3.6% G1; 4.8% G2, 13.3% G3, 10.8% G4), peripheral motor neuropathy (22.9% overall, 13.3% G1, 6.0% G2, 3.6% G3), and mucositis (20.5% overall, 16.9% G1, 2.4% G2, 1.2% G3). FACT-B Breast Cancer Concern (BCC) and Trial Outcome Index (TOI) scores were stable during therapy. The greatest mean improvement in summed BCC (mean change 3.3) and TOI (mean change 7.9) compared to baseline occurred at cycle 9 in pts with stable disease. Changes from baseline in the NTX and TOI of FACT-NTX worsened during the first 7 cycles of therapy (mean changes NTX 5.3, TOI 4.8). Pharmacogenomic analysis exploring host polymorphisms and development of neuropathy is ongoing. Conclusions: PROs are indispensable in the evaluation of anti-cancer agents in clinical trials. In this phase II trial, E demonstrated activity and safety in early lines of therapy for HER2- MBC. Additionally, improved QOL metrics were observed among pts experiencing stable disease. CTCAE rates of severe neuropathy were low, however PRO testing by FACT-NTX highlights progressive worsening of neurotoxicity. In contrast to classic CTCAE criteria producing aggregate estimates of toxicity, this phase II trial shows longitudinal collection of PROs provides meaningful, complementary, and dynamic clinical information. Citation Format: Metzger O, Lin NU, Schneider B, Faggen M, Come S, Openshaw T, Constantine M, Walsh J, Giobbie-Hurder A, Burstein HJ, Mayer EL. A phase 2 study of eribulin as early-line treatment for HER2- MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-08." @default.
• W2594672174 created "2017-03-16" @default.
• W2594672174 creator A5000955812 @default.
• W2594672174 creator A5009389041 @default.
• W2594672174 creator A5015383684 @default.
• W2594672174 creator A5022319770 @default.
• W2594672174 creator A5022511879 @default.
• W2594672174 creator A5024863982 @default.
• W2594672174 creator A5032886423 @default.
• W2594672174 creator A5042789036 @default.
• W2594672174 creator A5058033516 @default.
• W2594672174 creator A5071788399 @default.
• W2594672174 creator A5075445443 @default.
• W2594672174 date "2017-02-15" @default.
• W2594672174 modified "2023-09-27" @default.
• W2594672174 title "Abstract P5-15-08: A phase 2 study of eribulin as early-line treatment for HER2- MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes" @default.
• W2594672174 doi "https://doi.org/10.1158/1538-7445.sabcs16-p5-15-08" @default.
• W2594672174 hasPublicationYear "2017" @default.
• W2594672174 type Work @default.
• W2594672174 sameAs 2594672174 @default.
• W2594672174 citedByCount "0" @default.
• W2594672174 crossrefType "proceedings-article" @default.
• W2594672174 hasAuthorship W2594672174A5000955812 @default.
• W2594672174 hasAuthorship W2594672174A5009389041 @default.
• W2594672174 hasAuthorship W2594672174A5015383684 @default.
• W2594672174 hasAuthorship W2594672174A5022319770 @default.
• W2594672174 hasAuthorship W2594672174A5022511879 @default.
• W2594672174 hasAuthorship W2594672174A5024863982 @default.
• W2594672174 hasAuthorship W2594672174A5032886423 @default.
• W2594672174 hasAuthorship W2594672174A5042789036 @default.
• W2594672174 hasAuthorship W2594672174A5058033516 @default.
• W2594672174 hasAuthorship W2594672174A5071788399 @default.
• W2594672174 hasAuthorship W2594672174A5075445443 @default.
• W2594672174 hasConcept C121608353 @default.
• W2594672174 hasConcept C126322002 @default.
• W2594672174 hasConcept C143998085 @default.
• W2594672174 hasConcept C203092338 @default.
• W2594672174 hasConcept C2775930923 @default.
• W2594672174 hasConcept C2776387010 @default.
• W2594672174 hasConcept C2776694085 @default.
• W2594672174 hasConcept C2777511904 @default.
• W2594672174 hasConcept C2778715236 @default.
• W2594672174 hasConcept C2780739268 @default.
• W2594672174 hasConcept C29730261 @default.
• W2594672174 hasConcept C31760486 @default.
• W2594672174 hasConcept C530470458 @default.
• W2594672174 hasConcept C535046627 @default.
• W2594672174 hasConcept C71924100 @default.
• W2594672174 hasConceptScore W2594672174C121608353 @default.
• W2594672174 hasConceptScore W2594672174C126322002 @default.
• W2594672174 hasConceptScore W2594672174C143998085 @default.
• W2594672174 hasConceptScore W2594672174C203092338 @default.
• W2594672174 hasConceptScore W2594672174C2775930923 @default.
• W2594672174 hasConceptScore W2594672174C2776387010 @default.
• W2594672174 hasConceptScore W2594672174C2776694085 @default.
• W2594672174 hasConceptScore W2594672174C2777511904 @default.
• W2594672174 hasConceptScore W2594672174C2778715236 @default.
• W2594672174 hasConceptScore W2594672174C2780739268 @default.
• W2594672174 hasConceptScore W2594672174C29730261 @default.
• W2594672174 hasConceptScore W2594672174C31760486 @default.
• W2594672174 hasConceptScore W2594672174C530470458 @default.
• W2594672174 hasConceptScore W2594672174C535046627 @default.
• W2594672174 hasConceptScore W2594672174C71924100 @default.
• W2594672174 hasLocation W25946721741 @default.
• W2594672174 hasOpenAccess W2594672174 @default.
• W2594672174 hasPrimaryLocation W25946721741 @default.
• W2594672174 hasRelatedWork W10233532 @default.
• W2594672174 hasRelatedWork W13328401 @default.
• W2594672174 hasRelatedWork W14333088 @default.
• W2594672174 hasRelatedWork W16909223 @default.
• W2594672174 hasRelatedWork W18214132 @default.
• W2594672174 hasRelatedWork W1852032 @default.
• W2594672174 hasRelatedWork W2337926 @default.
• W2594672174 hasRelatedWork W4741852 @default.
• W2594672174 hasRelatedWork W5038423 @default.
• W2594672174 hasRelatedWork W9890510 @default.
• W2594672174 isParatext "false" @default.
• W2594672174 isRetracted "false" @default.
• W2594672174 magId "2594672174" @default.
• W2594672174 workType "article" @default.